Easton: Comb. risk distr. for known risk factors:4% are high risk; of these 18% for br ca; 20% are low risk. BRCA is 0.4% #MAPonco16
11:54am September 23rd 2016 via Hootsuite
Easton: He analysed the commercial test genes here '15 ref https://t.co/wdcObMvPfd and showed a chart of risk est. of genes #MAPonco16
11:50am September 23rd 2016 via Hootsuite
Easton: Shows Myriad's myRisk, Ambry's BreastNext, GeneDx. 'Not much consistency in what these co's offer'. 'Data is rather poor' #MAPonco16
11:48am September 23rd 2016 via Hootsuite
RT @jsoriamd: #MAPonco16 Douglas Easton breast cancer risk prediction https://t.co/cMNJxWR2T2
11:47am September 23rd 2016 via Twitter Web Client
Easton: Risk for all br ca: 9-10%; but first quartile is 18%. ER+ disease, more SNPs, better prediction. Effect of fam history #MAPonco16
11:47am September 23rd 2016 via Hootsuite
Easton: Predom. pathway for br ca by GWAS is FGF signalling. Risk has to use all the var's combined. https://t.co/BHqzEAg8UH #MAPonco16
11:45am September 23rd 2016 via Hootsuite
Easton: Most SNPs are enhancer-enriched; one example of fine-mapping here '16 ref https://t.co/enUXBmkMG3 #MAPonco16
11:44am September 23rd 2016 via Hootsuite
Easton: iCOGS and OncoArray studies, 50K/53K and 60K/88K cases/ctrls, not yet finished yet. #MAPonco16
11:40am September 23rd 2016 via Hootsuite
Easton: Relative risk vs Allele frequency for Br Ca: NBBC genes to the upper left; risk SNPs on the lower right. BRCA1/2 outliers #MAPonco16
11:38am September 23rd 2016 via Hootsuite
Douglas Easton (Cambridge, UK) Risk predictionin breast cancer #MAPonco16
11:37am September 23rd 2016 via Hootsuite
Garraway: A paradox - higher-order combinations are too toxic; new delivery? new dosing? #MAP16
11:06am September 23rd 2016 via Hootsuite
Garraway: Able to show MTAP rescue; effort on PRMT5 depletion, a therapeutic window. Illus. a new method for combinations #MAP16
11:05am September 23rd 2016 via Hootsuite
Garraway: Targeting MTAP loss - perhaps methylosome complex may be a mechanism '16 Science https://t.co/76b0D2He7N #MAP16
11:02am September 23rd 2016 via Hootsuite
Garraway: Expansion of targets = expand combinations. CCLE, Project Achillles: found unexpected synth lethal https://t.co/HrIg98ipKO #MAP16
11:00am September 23rd 2016 via Hootsuite
Garraway: Rational combinations: multiple hits across principles of resistance? Pathway reactivation, pathway-indifferent, etc #MAP16
10:58am September 23rd 2016 via Hootsuite
Garraway: AXL high-state, other genes ID'd; a by-pass model (CREB activation). (RAFi+MEKi resistance conversion states) #MAP16
10:57am September 23rd 2016 via Hootsuite
Garraway: Resistance that they may not see: chart the 'resistome' by transcriptional output. Clusters of MAPK reactivation #MAP16
10:56am September 23rd 2016 via Hootsuite
Garraway: Not really have used this before - exhaustion vs. cytotoxicity. Onto resistance - reviews models of resistance mech's #MAP16
10:54am September 23rd 2016 via Hootsuite
Garraway: T-cell expression in melanoma - subdivided to CD4+ etc. Can see 'high exhaustion at the single-cell level' #MAP16
10:50am September 23rd 2016 via Hootsuite
Garraway: 'Each tumor has single cells that are members of both classes'. MITF vs AXL - becoming a theme across ca types #MAP16
10:49am September 23rd 2016 via Hootsuite
Garraway: Single-cell RNA-seq: fruit salad vs smoothie. BRAF-mutant melanoma '14 ref https://t.co/ysxPg1TmsP bulk cp to single-cell #MAP16
10:48am September 23rd 2016 via Hootsuite
Garraway: After 10 mos; 1/2 the cases at least 6 cores. Able to get multiple cfDNA. All for mBrCa. n=94 #MAP16
10:45am September 23rd 2016 via Hootsuite
Garraway: Some samples to genomic and transcriptome; 1 to CLIA; others to single-cell analyses #MAP16
10:44am September 23rd 2016 via Hootsuite
Garraway: Shows busy slide of their workflow - serial tissue or blood biopsies. Punches, multiple cores, or fluid including blood #MAP16
10:43am September 23rd 2016 via Hootsuite
Garraway: Mutational load correlates to clinical benefit; but by itself, could not distinguish between responders/non-resp #MAP16
10:42am September 23rd 2016 via Hootsuite
Garraway: CDK inhib in br ca: CDKN2A dels, CCND1 ampl, not predictive. 'Molecular determinants of response not clearly understood' #MAP16
10:41am September 23rd 2016 via Hootsuite
Garraway: With a long tail: will the % of pts to benefit too small? Is the implied framework too narrow? #MAP16
10:40am September 23rd 2016 via Hootsuite
Garraway: ERCC2 shows up in other cancer types, where platinum Rx not thought about before #MAP16
10:39am September 23rd 2016 via Hootsuite
Garraway: Thus a subset could be ID'd of bladder ca, sensitive to cisplatin. 100% response rate just published (JAMA) #MAP16
10:38am September 23rd 2016 via Hootsuite
Garraway: Shows long-tail diagram from this '14 ref https://t.co/tdkFJHtj7C In bladder: one gene common: ERCC2 in responders #MAP16
Garraway: The 'basket trial' (1-gene, 1-drug) 'is insufficient'. Knowledge of resist. mech incomplete; rational combinations uncommon #MAP16
10:35am September 23rd 2016 via Hootsuite
Garraway: Monitor target over time: rational deployment, 'real-time optimization' of combination Rx for durable disease control #MAP16
10:34am September 23rd 2016 via Hootsuite
Garraway: Combination Rx - 'index' dependencies, immunologic vulnerabilities, prevalent resistance mechanisms #MAP16
10:33am September 23rd 2016 via Hootsuite
Garraway: One anchor: genetic/molecular stratification. Somatic genetics - about 90% of effort. 'But not sufficient' - immuno? #MAP16
10:32am September 23rd 2016 via Hootsuite
Garraway: 11K pts enrolled for enrolling, KBs, clinical trial options, targeted Rx. But ;what might success look like?' #MAP16
10:31am September 23rd 2016 via Hootsuite
Garraway: Now 137-gene, to 700-gene (called OncoPanel) '12. From Proof of Concept, to Development to Clinical implementation #MAP16
10:30am September 23rd 2016 via Hootsuite
Garraway: 'We started with what seems now what should belong in a museum, genotyping by Mass-Spec' ('07 'OncoMap') #MAP16
10:29am September 23rd 2016 via Hootsuite
Garraway: Starts with figure from '13 review https://t.co/HYnuiObPLu Schematic of Patient, 'omic profiling etc. #MAP16
10:28am September 23rd 2016 via Hootsuite
Levi Garraway (Dana-Farber, Boston MA) New Frontiers in Cancer Precision Medicine #MAP16
10:26am September 23rd 2016 via Hootsuite
Hadrup: Barcoding individual MHC complexes, can sort, amplify, and detect '16 Nature Biotech ref https://t.co/V6CJ4ncChk #MAP16
10:08am September 23rd 2016 via Hootsuite
Hadrup: Single-staining of MHC multimers/flow cytometry dates back to Altman 1996. Now use NGS for Ag-responsive T-cells #MAP16
10:07am September 23rd 2016 via Hootsuite
Hadrup: Shows PFS curves, and involvement of immune variation. Their tool - MuPeXi, neo-epitope prediction. https://t.co/zHuSQwqDvI #MAP16
10:06am September 23rd 2016 via Hootsuite
Hadrup: Immune surveillance involves TCR and CD8 on T-cells; MHC-I on cancer cell; mutated MHC can hide cancer antigen #MAP16
10:04am September 23rd 2016 via Hootsuite
Sine Reker Hadrup (Univ Denmark, Copenhagen, Denmark) Integrating cancer genomics with immune phenotyping #MAP16
10:02am September 23rd 2016 via Hootsuite
Lambin: Radiomics publication describing technique: '12 ref https://t.co/FReog6mxcr #MAP16
9:55am September 23rd 2016 via Hootsuite
Lambi: Used CT contrast that clusters very well with patient outcome data. Showed K-M curves for NSCLC and Head-and-Neck ca's #MAP16
9:53am September 23rd 2016 via Hootsuite
Philippe Lambin (Maastricht, Netherlands): Molecular radio-oncology #MAP16 Can quantitative information be extracted from imaging data?
9:45am September 23rd 2016 via Hootsuite
AZ: Shows PFS data from Oxnard '16 ref https://t.co/X0lbObBn4X Plasma is pending US approval #MAP16
8:36am September 23rd 2016 via Hootsuite
AZ: Shows summary results from these two ctDNA T790M studies https://t.co/AsBbz6LOri https://t.co/LGIufOP4q8 #MAP16
8:34am September 23rd 2016 via Hootsuite
AZ: Only 2.5y from discovery to approval, needed a T790M, Roche-developed cobas assay. #MAP16
8:29am September 23rd 2016 via Hootsuite
